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a b s t r a c t
It is now well established that reactive oxygen species (ROS), reactive nitrogen species (RNS), and a basal
level of oxidative stress are essential for cell survival. It is also well known that while severe oxidative
stress often leads to widespread oxidative damage and cell death, a moderate level of oxidative stress,
induced by a variety of stressors, can yield great beneﬁcial effects on adaptive cellular responses
to pathological challenges in aging and aging-associated disease tolerance such as ischemia tolerance.
Here in this review, I term this moderate level of oxidative stress as positive oxidative stress, which
usually involves imprinting molecular signatures on lipids and proteins via formation of lipid peroxida-
tion by-products and protein oxidation adducts. As ROS/RNS are short-lived molecules, these molecular
signatures can thus execute the ultimate function of ROS/RNS. Representative examples of lipid
peroxidation products and protein oxidation adducts are presented to illustrate the role of positive
oxidative stress in a variety of pathological settings, demonstrating that positive oxidative stress could be
a valuable prophylactic and/or therapeutic approach targeting aging and aging-associated diseases.
& 2014 The Author. Published by Elsevier B.V. All rights reserved.
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Introduction
Production of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) is part of normal aerobic cellular metabolism [1–5].
While RNS generally originate from nitric oxide synthases, ROS
can be generated by a variety of enzymes and metabolic pathways,
including mitochondrial complexes I–III [6–9] in the electron trans-
port chain, dihydrolipoamide dehydrogenase in the α-keto acid
dehydrogenase complexes [10–14], NADPH oxidase [15,16], xanthine
oxidase [17,18], monoamine oxidase [19], and cytochrome P450
proteins [20]. All of these systems may result in oxidative stress
under appropriate conditions. Although basal levels of ROS/RNS are
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indispensible for redox signaling and cell survival [21,22], high levels
of ROS/RNS would be detrimental to cells and have been thought to
contribute to aging and the pathogenesis of numerous aging-related
diseases [22,23]. On the other hand, a moderate level of oxidative
stress, reﬂected by a moderate level of ROS/RNS production, could be
induced and modulated to produce an adaptive cellular response
that is beneﬁcial for cell survival [22–27].
Oxidative stress is a situation whereby cellular levels of ROS or
RNS overwhelm the cellular antioxidant capacities [20]. This
condition, when severe, usually leads to extensive modiﬁcations
or damage to macromolecules including DNA, lipids and proteins
[28,29]. Collectively, these damaged macromolecules, when
beyond the cell0s reparative and degradative activities, can even-
tually induce cell death and tissue injury [22,25]. Nonetheless,
increasing evidence has now established that many protein
oxidation or lipid oxidation products can be beneﬁcial for cell
survival [29–32]. These oxidation products are usually caused by a
moderate level of oxidative stress, which is termed here as positive
oxidative stress. This is the type of oxidative stress that can induce
or is part of an adaptive response that protects cells against
subsequent severe challenges that otherwise would trigger wide-
spread oxidative damage and cell death [23,27].
In order to create a positive oxidative stress condition, it is
necessary to stress cells with a stressor [22,27]. Many stressors,
when used at appropriate dosages, can elicit a moderate or non-
lethal level of oxidative stress in the absence of cytotoxicity and
cell death [27]. Nonetheless, it should be pointed out that if used at
higher dosages; almost all stressors will inevitably yield toxicity
that leads to cell death.
The best examples of positive oxidative stress would be ische-
mic tolerance including preconditioning and postconditioning,
which are clinically-relevant approaches applied in a variety of
animal models for protection of tissues against ischemia-induced
injuries [33–35]. It has been well-demonstrated that a variety of
stressors, such as, mitochondrial electron transport chain inhibi-
tors [36], hypoxia [37], hyperoxia [38,39], hyperthermia [40] and
hypothermia [41], as well as short episodes of ischemia [42] can
induce positive oxidative stress via a transiently increased ROS
production that is involved in an adaptive response for prophy-
lactic purposes (Table 1) [43–49]. Accordingly, many studies have
shown that antioxidants administered prior to or at the onset
of preconditioning or postconditioning induction, can abolish
the preconditioning or postconditioning effect [34,35,50,51], thus
demonstrating that ROS and oxidative stress are essential for
preconditioning or postconditioning to take effect [52–54]. Inter-
estingly, the effects of preconditioning and postconditioning are
only evident in severe pathological challenges such as an extended
period of ischemia or reperfusion.
So how does positive oxidative stress work? As ROS and RNS
are short-lived molecules, they themselves cannot impart a
persistent beneﬁcial effect [22]. It is thus believed that the targets
of ROS and RNS would serve as molecular signatures [23] that
relay and extend the beneﬁcial effects of positive oxidative stress
[22]. These molecular signatures are those of ROS/RNS modiﬁed
oxidative products such as lipid peroxidation by-products and
protein oxidation adducts. Chemically, numerous protein oxidative
modiﬁcations involved in positive oxidative stress are reversible such
as disulﬁde formation [55–60], S-glutathionylation [61–64], S-sulfena-
tion [65–67], and S-nitrosylation [68–71]. These enhanced modiﬁca-
tions usually play regulatory roles in protein function and thus can
elicit great protective effects against cell death induced by a variety of
severe stress conditions. As has been reported, all these reversible
cysteine modiﬁcations can occur under basal conditions [72–79]. In
the absence of positive oxidative stress, however, these basal level
modiﬁcations may have no apparent protective effects owing to their
low abundance.
Herein to demonstrate the role of positive oxidative stress in
aging and aging-associated diseases, I would like to present a few
selected representative examples of oxidative molecular signa-
tures that are beneﬁcial for cell survival. These examples include
lipid peroxidation products and protein oxidation adducts.
Positive effect of lipid peroxidation products
Lipid peroxides in hemoglobin-modiﬁed low density lipoprotein are
beneﬁcial for cell survival
Hemoglobin (Hb) can modify low density lipoproteins (LDL),
and lipid oxidation of the latter is usually linked to pathogenesis of
atherosclerosis [31]. However, while hemoglobin-binding of LDL
renders the complex (Hb–LDL) highly susceptible to lipid perox-
idation, such oxidation products are not cytotoxic [31]. The reason
for this is that oxidized Hb–LDL could induce HO-1 (hemeoxygen-
ase-1) expression, likely via the activation of the Nrf2 transcription
factor [80]. Notably, when oxidized Hb–LDL was reduced by
ebselen, HO-1 induction was inhibited [31]. Therefore, oxidized
Hb–LDL can exhibit a beneﬁcial effect via HO-1 induction.
Table 1
Popular stressors known to induce positive oxidative stress. Many of these stressors have been studied in the context of tissue ischemic tolerance.
Stressors Beneﬁcial effects Selected references
3-Nitropropionic acid Complex II inhibitor, ischemic tolerance [83–85]
Rotenone Complex I inhibitor, ischemic tolerance [86]
Antimycin A Complex III inhibitor, ischemic tolerance [86]
Diazoxide kATP channel opener, ischemic tolerance [87]
Cyanide Complex IV inhibitor, ischemic tolerance [53]
Cobalt chloride Chemical hypoxia/HIF-1 activation [88,89]
Carbon monoxide ROS-mediated prevention of apoptosis [61]
Isoﬂurane Induction of pre- and postconditioning [90,91]
Short episodes of ischemia Ischemic tolerance [92–94]
Hypoxia/intermittent hypoxia Ischemic tolerance [37,95]
Hyperoxia Ischemic tolerance [38,39]
Hyperthermal stress Ischemic tolerance [40]
Hypothermal stress Ischemic tolerance [41]
Remote preconditioning Ischemic tolerance [96–98]
Physical exercise Production of beneﬁcial ROS [50]
Hydrogen peroxide Ischemic tolerance [99,100]
Ozone Ischemic tolerance [101,102]
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Beneﬁcial effect of a cholesterol oxidation product
24-S-hydroxycholesterol (24-SOHC) is endogenously produced
in the brain and plays an important role in brain cholesterol
homeostasis. Okabe et al. recently showed that 24-SOHS could
elicit an adaptive response in human neuroblastoma SH-SY5Y cells
[81]. They found that cells treated with 24-SOHC at non-lethal
levels could signiﬁcantly attenuate cell death induced subse-
quently by 7-keto cholesterol (7KC). Furthermore, the attenuation
of cell death occurred in both differentiated and non-differentiated
cells, and could also be induced by other cholesterol oxidation
by-products such as 25-hydroxycholesterol and 27-hydroxy-
cholesterol. Moreover, 24-SOHC treatment upregulated the
expression of liver X receptor (LXR) target genes, thereby inducing
ATP-binding cassette transporter. When LXRβ was knocked down
by siRNA, the adaptive response was greatly diminished. There-
fore, 24-SOHC represents another example of positive oxidative
stress; which works via transcriptional activation of LXR signaling
pathway, leading to neuronal protection against further 7KC-
triggered cellular toxicity.
Positive effects of protein oxidation products
Cardioprotection by S-nitrosylation of a single cysteine residue on the
mitochondrial complex I subunit ND3
Mammalian mitochondrial complex I has at least 45 subunits
and many of them are redox-sensitive proteins that can undergo
redox modiﬁcations by ROS or RNS [82]. Recently, Chouchani et al.
reported that S-nitrosylation of the ND3 subunit within complex I
could protect cardiomyocytes against cell death induced by cardiac
ischemia reperfusion injury [30]. As this S-nitrosylation occurred
on cysteine-39 of ND3 and was induced by a mitochondria-
selective S-nitrosylating agent (named mitoSNO) administered at
the onset of reperfusion, the authors presented an excellent
postconditioning paradigm whereby the nitrosylation of a single
cysteine residue can trigger a positive oxidative stress condition
that protects against cardiac ischemic injury.
S-cysteine sulfenation of the Parkinson0s disease-associated protein
DJ-1 is neuroprotective
Parkinson0s disease (PD) is an age-related neurodegenerative
disorder. While it is known that mutations in the gene that
encodes DJ-1, a PD-related protein, can abolish neuroprotective
function, the underlying mechanisms have been elusive. Madian
et al. have recently provided convincing evidence that DJ-10s
protective function in PD is due to the conversion of a cysteine0s
sulfhydryl group (–SH) to an S-sulfenation product (–SOH) [32].
The authors further demonstrated that mutations occurring on the
DJ-1 gene that disrupted or interfered with this –SH to –SOH
conversion on cysteine residue 106 could abolish DJ-10s neuropro-
tective function. This study thus provides another example of ROS-
induced positive oxidative stress in age-related neurodegenerative
disease.
Summary
The above representative examples demonstrate that lipid perox-
idation by-products and protein oxidation adducts can have tremen-
dous prophylactic effects on aging-related diseases. Fig. 1 shows the
relative magnitudes of oxidative stress and the potential correspond-
ing effects. Basically, while a basal level of ROS/RNS and oxidative
stress is essential for cell survival [21,22], severe oxidative stress or
damage associated with a highly elevated level of ROS/RNS production
will inevitably impair the cells0 self-repair ability and thus can lead to
cell death [22]. Importantly, a moderate level of oxidative stress, i.e.,
positive oxidative stress, induced by a moderate level of ROS/RNS, can
be triggered by a variety of stressors to protect against further lethal
challenges that otherwise would cause cell death and tissue injury
[22,23,27].
Perspectives
Given that ROS/RNS are short-lived molecules and that the
molecular signatures imprinted by these ROS/RNS on lipids and
proteins can actually execute the ultimate function of positive
oxidative stress, including redox signaling and activation of
transcriptional factors [27], further studies will need to be under-
taken to identify more targets in a variety of stress settings.
Moreover, the underlying mechanisms of such identiﬁed targets,
especially their prophylactic roles in aging and aging-associated
disease tolerance will also need to be elucidated. It is the author0s
belief that induction of positive oxidative stress could serve as a
valuable prophylactic or therapeutic approach targeting aging and
aging-associated diseases.
Basal level oxidative stress 
that maintains homeostasis
Positive oxidative stress
induced purposely by 
non-lethal challenges 
Severe oxidative stress that 
induces damage and cell death
Severity of oxidative stress
Fig. 1. Levels of cellular oxidative stress and their differential effects. (A) basal level oxidative stress that is essential for cell survival and homeostasis; (B) positive oxidative
stress that can be induced by a variety of non-lethal challenges that often induce protein oxidative modiﬁcations; (C) Severe oxidative stress that induces damage and
cell death.
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